TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from LivaNova ( (LIVN) ) is now available.
On September 3, 2025, LivaNova PLC appointed Donald Zurbay to its Board of Directors and as a member of the Audit and Compliance Committee, effective September 4, 2025. Mr. Zurbay brings extensive experience from his leadership roles at Patterson Companies and St. Jude Medical, enhancing LivaNova’s strategic direction and governance.
The most recent analyst rating on (LIVN) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on LivaNova stock, see the LIVN Stock Forecast page.
Spark’s Take on LIVN Stock
According to Spark, TipRanks’ AI Analyst, LIVN is a Neutral.
LivaNova’s overall stock score is driven by strong earnings call performance and positive technical indicators, indicating potential growth. However, profitability challenges and valuation concerns weigh down the score. The legal dispute over environmental liabilities adds an element of risk.
To see Spark’s full report on LIVN stock, click here.
More about LivaNova
LivaNova PLC operates in the healthcare industry, focusing on medical technologies and devices.
Average Trading Volume: 664,330
Technical Sentiment Signal: Buy
Current Market Cap: $3.11B
Find detailed analytics on LIVN stock on TipRanks’ Stock Analysis page.